Walker Asset Management LLC Buys 78 Shares of Johnson & Johnson $JNJ

Walker Asset Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.5% during the second quarter, Holdings Channel reports. The firm owned 3,154 shares of the company’s stock after acquiring an additional 78 shares during the period. Walker Asset Management LLC’s holdings in Johnson & Johnson were worth $482,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the first quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $181.63 on Tuesday. The business’s 50-day moving average price is $174.76 and its 200-day moving average price is $162.18. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.87. The firm has a market capitalization of $437.43 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 2.29 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on JNJ shares. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Barclays raised their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Finally, Citigroup raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $181.40.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.